|
Press Releases |
|
 |
|
Wednesday, July 16, 2025 |
|
A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today |
On the morning of 15 July 2025, China Medical System Holdings Limited ("CMS" or the "Group") rang the ceremonial bell to mark its official listing on the Singapore Exchange Main Board (Stock Abbreviation: CMS, Stock Code: 8A8). more info >> |
|
Wednesday, June 25, 2025 |
|
China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange |
more info >> |
|
Friday, March 21, 2025 |
|
China Medical System (00867) Released its 2024 Annual Results: Focusing on Innovation and Specialty Breakthroughs to Reshape Growth Momentum |
On March 17, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 annual results. The Company recorded a turnover of RMB7,469 million, representing a year-on-year decrease of 6.8%; in the case that all medicines were directly sold by the Company, the turnover would be RMB8,622 million, representing a year-on-year decrease of 9.0%. more info >> |
|
Friday, February 14, 2025 |
|
China Medical System (867.HK) is Included in the S&P Global Sustainability Yearbook 2025 |
In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings Limited ("CMS" or the "Group") has been included in the S&P Global Sustainability Yearbook 2025 (the "Yearbook 2025"). more info >> |
|
Friday, January 24, 2025 |
|
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 |
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 more info >> |
|
Thursday, January 9, 2025 |
|
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type |
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the "Agreement") with Alpha Cognition Inc. ("Alpha") of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets)("ZUNVEY" or the "Product") for the treatment of mild-to-moderate dementia of the Alzheimer's type. more info >> |
|
Monday, December 9, 2024 |
|
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China |
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China more info >> |
|
Monday, December 2, 2024 |
|
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia |
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia more info >> |
|
Monday, October 21, 2024 |
|
China Medical System: First Ruxolitinib Cream's Prescriptions for Vitiligo Issued in the Greater Bay Area |
China Medical System Holdings Limited (the "Group" or "CMS") is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. more info >> |
|
Tuesday, September 24, 2024 |
|
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China |
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Hong Kong Shopping Festival Returns in August with Bigger and Better 2nd Edition
Jul 30, 2025 22:40 HKT/SGT
|
|
|
Naoris Protocol Announces Upcoming TGE for $NAORIS
Jul 30, 2025 22:00 HKT/SGT
|
|
|
Introducing the Meshy 5 Preview: Smarter AI, Cleaner Models, Bigger Animation Potential
Jul 30, 2025 22:41 JST
|
|
|
New Report Reveals Key Considerations For Successful Distribution Onboarding
Jul 30, 2025 21:00 HKT/SGT
|
|
|
Wintermar Offshore (WINS:JK) Reports 1H2025 Results
Jul 30, 2025 19:56 HKT/SGT
|
|
|
Production, Sales and Export Results for June, 2025
Jul 30, 2025 18:24 JST
|
|
|
Sales, Production, and Export Results for the First Half of 2025
Jul 30, 2025 18:06 JST
|
|
|
Ongoing Share Buybacks Demonstrate Confidence, Shoucheng Holdings Boosts Market Expectations with Concrete Action
Jul 30, 2025 11:00 HKT/SGT
|
|
|
Collaborative Development of Ultra-Compact and Lightweight Satellite Communication User Terminals for Mobility with Mitsubishi Chemical, NICT, and TECHLAB
Jul 30, 2025 11:00 JST
|
|
|
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Jul 29, 2025 23:13 HKT/SGT
|
|
|
Mitsubishi Heavy Industries Concludes Agreement with Modius to Provide DCIM Solutions for Data Centers Worldwide
Jul 29, 2025 20:00 JST
|
|
|
Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence
Jul 29, 2025 16:00 HKT/SGT
|
|
|
Set at the Osaka-Kansai Expo venue! Detailed program announced for the "OSAKA JAPAN SDGs Forum"
Jul 29, 2025 14:30 JST
|
|
|
GTJAI Achieved 'Carbon Neutrality' at Operational Level for the Third Consecutive Year
Jul 29, 2025 13:15 HKT/SGT
|
|
|
Unitree Races Toward IPO as Robot Applications Accelerate: Shoucheng Holdings Unlocks Dual-Engine Gains
Jul 29, 2025 11:30 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|